Research progress on pathogenesis and clinical treatment of neuromyelitis optica spectrum disorders (NMOSDs)

Clin Neurol Neurosurg. 2023 Aug:231:107850. doi: 10.1016/j.clineuro.2023.107850. Epub 2023 Jun 25.

Abstract

Neuromyelitis optica spectrum disorders (NMOSDs) are characteristically referred to as various central nervous system (CNS)-based inflammatory and astrocytopathic disorders, often manifested by the axonal damage and immune-mediated demyelination targeting optic nerves and the spinal cord. This review article presents a detailed view of the etiology, pathogenesis, and prescribed treatment options for NMOSD therapy. Initially, we present the epidemiology of NMOSDs, highlighting the geographical and ethnical differences in the incidence and prevalence rates of NMOSDs. Further, the etiology and pathogenesis of NMOSDs are emphasized, providing discussions relevant to various genetic, environmental, and immune-related factors. Finally, the applied treatment strategies for curing NMOSD are discussed, exploring the perspectives for developing emergent innovative treatment strategies.

Keywords: Astrocytopathic disorders; Etiology; Neuromyelitis optica spectrum disorder; Pathogenesis; Treatment options.

Publication types

  • Review

MeSH terms

  • Axons / pathology
  • Humans
  • Immunologic Factors / therapeutic use
  • Neuromyelitis Optica* / drug therapy
  • Neuromyelitis Optica* / therapy
  • Spinal Cord / pathology

Substances

  • Immunologic Factors